Factors influencing the accumulation of ciprofloxacin in Pseudomonas aeruginosa.
Ciprofloxacin accumulation in Pseudomonas aeruginosa was measured by a bioassay. Drug accumulation in strain PAO2 was compared with that of three spontaneous ciprofloxacin-resistant mutants selected with 0.5 micrograms of ciprofloxacin per ml. PAO4701 cfxA2 contains a mutation in the gyrA gene, PAO4742 cfxB5 may represent a permeability mutant based on pleiotropic drug resistance, and PAO4700 cfxA1 cfxB1 contains both types of mutations. In all strains, drug accumulation was similar, reaching steady state during the first minute of exposure. Drug accumulation was unsaturable over a range of 5 to 80 micrograms/ml, suggesting that ciprofloxacin accumulates by diffusion in P. aeruginosa. Although all four strains accumulated two- to sevenfold more ciprofloxacin in the presence of the inhibitor carbonyl cyanide m-chlorophenylhydrazone, the cfxB mutants accumulated two- to fourfold less drug than either PAO2 or the cfxA2 mutant. Polyacrylamide gel analysis revealed a protein common to cfxB mutants only, while all strains had similar lipopolysaccharide profiles. The results suggest that ciprofloxacin accumulation in P. aeruginosa is a complex phenomenon that may be affected by both an energy-dependent drug efflux process and outer envelope composition.
Celesk
R A
RA
Pharmaceutical Division, Miles Inc., West Haven, Connecticut 06516.
Robillard
N J
NJ
D001425:Bacterial Outer Membrane Proteins / Q000378:metabolism; D002874:Chromosome Mapping; D002939:Ciprofloxacin / Q000378:metabolism* / Q000494:pharmacology; D003470:Culture Media; D004579:Electron Transport; D004591:Electrophoresis, Polyacrylamide Gel; D008070:Lipopolysaccharides / Q000378:metabolism; D008826:Microbial Sensitivity Tests; D009154:Mutation; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*
D001425:Bacterial Outer Membrane Proteins; D003470:Culture Media; D008070:Lipopolysaccharides; D002939:Ciprofloxacin